We investigated impaired cellular immune responses of individuals on chronic hemodialysis by using monoclonal antibodies that trigger differential pathways of T cell activation. Reduced cellular reactivity, which exists in a high proportion of such patients, can be attributed to a failure of the monocyte population to support the process of primary T cell activation in vitro. This defect results in a lack of interleukin 2 production, which is critically dependent on a monocyte-derived signal. In contrast, T lymphocyte function was found to be physiologic. Perhaps more important, the degree of monocyte dysfunction in vitro correlated with the same patients' in vivo responses to hepatitis B vaccination. Addition of recombinant human interleukin 2 fully reconstituted their deficient immune response in vitro.
Introduction
Human T lymphocytes can be activated through differential pathways to express their functional repertoires (1) (2) (3) (4) (5) . Antigens in context with major histocompatibility complex determinants provide the first signal ofthe T3-Ti antigen receptormediated mode of T cell triggering, which is, in addition, critically dependent on accessory cell help (6) (7) (8) . In contrast, T cell activation via the T 1 sheep erythrocyte receptor glycoprotein represents an antigen independent "alternative pathway" that circumvents a monocyte requirement (5, 8, 9) . Besides natural ligands for these two sets of surface receptors, monoclonal antibodies exist that are capable of exhibiting ligandlike agonistic effects (3) (4) (5) 10) .
We investigated in vitro functions of peripheral blood mononuclear cells from individuals with deficient primary immune responses in vivo by employing such monoclonal antibodies (anti-T3, anti-Tl 12, anti-Tl 13) as stimuli. Immunodeficiency in these patients is secondary to chronic renal failure (1 1-19) and can be quantitated by means of the individual capacity to mount a primary immune response to hepatitis B vaccine. In this regard, controlled efficacy studies in the United States and Europe recently demonstrated that a high proportion of uremic patients fail to respond to otherwise highly immunogenic vaccines (20) (21) (22) (23) (24) (25) (26) (27) .
The studies reported below indicate that nonresponsiveness to hepatitis B vaccination in this group of individuals acetic acid transaminase, serum glutamic pyruvic transaminase, y-glutamyl transferase, alkaline phosphate, total bilirubin, IgG, and IgM.
According to anti-HBsAg titers, patients were grouped as follows:
Responders (R).' Seroconversion occurred 12 mo after standard vaccination; anti-HBs positivity in two consecutive control patients (13, (16) (17) (18) (19) (20) (21) (22) (23) (24) .
Nonresponders (NR). At no time point was anti-HBs detectable (patients 1-7, 22, 23) .
Weak responders (WR). Low titers following vaccination (between two and four times the negative control value); anti-HBs positivity in one of two consecutive controls (C); no seroconversion after standard vaccination (patients 8-12, 14, 15 
Purified T cells and monocytes
Purified T cells were prepared by E-rosetting with sheep red blood cells. Subsequently, E+ and E-were individually plated onto glass Petri dishes and incubated overnight at 37°C, 6% CC2, humidified atmosphere in culture medium RPMI 1640 supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and 2% L-glutamine (Gibco Laboratories, Grand Island, NY).
To further deplete monocytes nonadherent E+ cells were further incubated with monoclonal antibodies anti-12 (28) and anti-Mo2 (29) (final dilution 1:200 ascites in medium) for 30 min 370, then washed once and subsequently treated with preabsorbed rabbit serum as a source of complement for 60 min 37°C in a shaking water bath. After three washes cells were adjusted to 2 X 106 cells/ml and incubated overnight in standard culture medium and employed as a source of purified resting T lymphocytes. Adherent E-cells, incubated onto glass Petri dishes for 48 h in culture medium were gently removed with a rubber policeman and employed as a source of monocytes.
Cell viability as determined by trypan blue exclusion was 90%. Purified T cell preparations were reanalyzed for reactivity with antiTl 1 (T lineage specific) and anti-Mo2 (monocyte specific). Briefly, anti-Tl 1 reactivity in all cases exceeded 96% and was 99% in 23 of the 27 individuals investigated. Anti-Mo2 reactivity was always in the range of the negative control.
Lymphokines and mitogens Recombinant human interleukin 2 (rec I1-2) was a generous gift of Sandoz (Vienna, Austria). Phytohemagglutinin (PHA-P) was purchased from Wellcome Laboratories (Burgwedel, FRG).
1. Abbreviations used in this paper: C, control; IL-2, interleukin 2; NR, nonresponders; WR, weak responders.
Monoclonal antibodies
Monoclonal antibody anti-T3 (IgGj) was purified from ascites employing Sepharose protein A (Pharmacia, Uppsala, Sweden) according to the method ofEy et al. (30) . Subsequently, 3 mg of purified antibody were coupled to 1 ml of swollen CnBr-activated Sepharose beads (Pharmacia) (3). Anti-Tl 12 and anti-Tl 13 were produced and characterized as previously described (5) The various stimuli (anti-T3-Sepharose, anti-Tl 12+ anti-Tl 13 and PHA-P) were employed at concentrations that mediated comparable levels of (3H]thymidine uptake when titered on healthy control individuals.
Expression ofIL-2 receptors 2 X 105 T cells/sample prepared and pretreated as described in Table 2 were incubated with 5 1 of 251-interleukin 2 (purchased from Amersham Laboratories, Buckinghamshire, England) (-1 X 106 cpm) for 1 h at 4°C. Subsequently, individual samples were washed three times with cold medium. Prior to analysis in an LKB gamma-spectrometer, cells were transferred into fresh tubes. To distinguish specific from nonspecific IL-2 binding '25I-IL-2 in the presence of an anti-IL-2 receptor antibody at saturating concentrations was investigated. It should be noted that due to the very limited numbers ofcells that could be obtained from dialysis patients and the need to perform, in parallel, phenotypic, functional, and IL-2 binding studies it was not possible to perform extensive IL-2 binding experiments.
To investigate expression ofthe Tac 
Results
In the present study we have investigated 23 uremic patients on chronic hemodialysis and a group of healthy individuals with regard to cellular immune responses in vitro. All individuals had been vaccinated against hepatitis B prior to the present analysis (21) and grouped according to their anti-HBs serum titers as, respectively, R, WR, and NR (see Methods).
Given this inability of the two latter groups to mount a physiologic primary immune response in vivo, we investigated how their T lymphocytes respond to an antigenlike stimulus (i.e., anti-T3 in Sepharose-linked form: S-anti-T3) (3). This monoclonal antibody is directed at a nonpolymorphic subunit of the human T3-Ti antigen receptor complex and can exhibit functional effects that are indistinguishable from those mediated by the natural ligand ofT3-Ti, namely antigen itself. As shown in Table I , S-anti-T3 alone was not mitogenic for resting T lymphocytes. However, in the presence of 5% irradiated autologous monocytes, proliferation to S-anti-T3 could be detected. Perhaps more important, the levels of [3H]thymidine incorporation were found to be very distinct among the patients investigated. Thus, whereas patients 4 and 5, representative for a group of 7 NRs to vaccination mounted little if any responses, WR 13 and 10 had reduced but detectable responses and [3H]thymidine uptake of T lymphocytes from patients 19 and 23 appeared to be comparable to the healthy control individuals investigated (I, II). It should be noted that patient 19 was a vaccine responder, whereas patient 23 was a nonresponder. Additional but less pronounced differences among these patients existed regarding in vitro responses after PHA stimulation (Fig. 1) .
Lymphocyte proliferation after antigen-like stimuli is known to be dependent on an efficient interaction between T cells and monocytes (6) (7) (8) . Therefore, we investigated whether impaired responses of dialysis patients to S-anti-T3 stimulation were due to a defect either at the level ofT lymphocytes or monocytes, or both. Thus, T cells from each patient were individually combined with monocytes (5%) from a healthy individual and stimulated with S-anti-T3. As shown in Table I, fifth line, proliferative responses were obtained in all patients under these conditions. In contrast, no significant differences could be observed whether autologous or "healthy" irradiated monocytes were added to the T cell population of healthy controls and uremic responders to vaccination (e.g., patient 19). This result supports the view that impaired monocyte function may exist in a high proportion of uremic patients. In contrast, T cell function appeared to be physiologic. To further substantiate the former point, purified T cells from a healthy control person were individually incubated with monocytes (5%) from each uremic patient, and subjected to anti-T3 stimulation. As shown in Table I , seventh line, monocytes from patients who failed to support T cell blastogenesis in the autologous combination functioned much less well in supporting blastogenesis of "healthy" T lymphocytes than did monocytes from individuals with a normal response to anti-T3 stimulation. Clonal T cell expansion directed by antigen occurs by means of the IL-2 receptor system (31) (32) (33) (34) (35) . It follows that a deficient proliferative response can be due to either impaired IL-2 receptor expression, reduced IL-2 production, or both. Given the relation of the T3-Ti antigen receptor to the IL-2 receptor (10), expression of functional IL-2 receptors on T cells can be determined by means of acquisition of IL-2 responsiveness after antigen-receptor stimulation. To investigate this point, purified populations of T lymphocytes of the various patients were obtained and incubated in the presence or absence of S-anti-T3. The extent of in vitro proliferation to a constant dose of recombinant IL-2 (rIL-2) (2 ng/ml) was then taken as an indication for the capacity to express functional IL-2 receptor molecules. As shown in Fig. 2 , the capacity of T cells to respond to IL-2 after this antigenlike stimulation was markedly enhanced in most patients with impaired responses to anti-T3 stimulation (compare Table I and Fig. 1 ) (NR and WR).
Given these very differing proliferative responses to a constant concentration of exogenous rIL-2 after T cell receptor triggering, it was necessary to investigate IL-2 receptor expression by T lymphocytes from representative vaccine responders and nonresponders. To this end, purified T lymphocytes were obtained from patients 2 (NR), 4 (NR), 17 To further exclude that reduced IL-2 production was indeed not due to a defect at the T cell level we investigated, in addition, the proliferative responses of T lymphocytes to triggering via the "alternative pathway" of T cell activation (5) . Although this pathway is engaged via a T cell antigen-receptor unrelated glycoprotein (T I 1), proliferation is dependent on an intact IL-2/IL-2 receptor system as well. However, Tl 1 triggering induces both IL-2 production and IL-2 receptor expression in the absence of monocyte help (5, 8) . As shown in Fig. 4 , "alternative pathway" triggering by monoclonal antibodies resulted in comparable levels of [3H]thymidine incorporation in all patients and control individuals tested. Given that defective IL-2 production was most likely underlying nonresponsiveness to S-anti-T3, in a final set of experiments we investigated whether addition of recombinant human IL-2 was capable of circumventing this NR state. To this end, T cells and autologous monocytes of each patient were incubated with S-anti-T3 and proliferation determined in the presence or absence of rIL-2. Table III gives representative experimental results of two nonresponders (patients 5 and 6) and one responder (patient 19). As shown, rIL-2 completely restored the deficient proliferative response, whereas addition of the same low concentration of rIL-2 in the case of the responder (patient 19), produced only a weak if any additional mitogenic effect. 
Discussion
With the advent of monoclonal antibodies directed at unique T cell differentiation antigens, new strategies to probe cellular immune responses have evolved. Unlike lectins, which mediate multiple and complex effects, monoclonal antibodies directed at defined T cell surface structures and known to selectively inducing differential pathways of T cell activation (3, 5) can now be employed as probes to define, in much greater detail, a given individual's cellular immune function. In the present study we have utilized mitogenic monoclonal antibodies directed at the, respectively, T3-Ti antigen recognition complex of human T lymphocytes (1-3, 10 ) and the T lineage specific TI 1 cell surface glycoprotein (5) (21) , were utilized to judge the validity of the in vitro data obtained.
After activation of monocyte-reconstituted T lymphocytes by S-anti-T3, a reagent that is known to mediate an antigenlike signal (3), a high proportion of patients with impaired responses to vaccination presented with deficient in vitro proliferation as compared to healthy control individuals and uremic vaccine responders (Table I, Fig. 1 ). This defect appeared, however, not to be due to abnormalities at the level of the T cell but rather to a profound incapacity of such patients' monocytes to support the process of primary T cell activation (Table I and Fig. 1 ). Perhaps more important, a striking correlation between monocyte dysfunction in vitro and the in vivo response to hepatitis vaccination was found. Thus, only 2 of the 27 individuals tested, namely patients 22 and 23, were nonresponders to vaccination in spite of an apparently "normal" cellular immune function in vitro (Fig. 1, Table I ). It should be noted that even among healthy individuals a nonresponder rate of -5% has been reported. This indicates that defects other than those investigated here can lead to nonresponsiveness after exposure to particular foreign antigens. However, at least with regard to immunodeficient uremic patients, deficient monocyte function is a likely explanation in the majority of cases.
In a previous study regarding cellular immune functions of uremic individuals deficient T lymphocyte responses were observed (19) . These experiments were performed employing unseparated T cells and monocytes and, therefore, as discussed, the reasons of reduced cellular proliferation and IL-2 production by T lymphocytes remained unclear. Nevertheless, these earlier results are in line with the present data, which demonstrate reduced T cell activities as a consequence of monocyte failure.
One contribution of monocytes in the generation of a primary immune response is believed to be the secretion of With this regard, a number of recent reports suggested that anti-T3 monoclonal antibodies plus IL-I can synergize in inducing T cell proliferation (8, (36) (37) (38) Besides the finding that T cells from uremic nonresponders to vaccination reacted in a normal fashion to alternative pathway stimulation (Fig. 3) , the expression of IL-2 receptors that critically determines the extent of clonal T cell expansion after an antigenic stimulus (10) , occurred even stronger the more immunodeficient the respective patients presented in vitro and in vivo (Fig. 2, 3 and Table II) . One explanation for this finding is that uremic patients indeed suffer from low levels of endogenous IL-2 and, therefore, a feedback mechanism that controls IL-2 receptor expression may not be functional in a physiologic fashion. This conclusion is supported by our recent finding that T cells from uremic patients, when stimulated with mitogens or alloantigens, produce significantly less IL-2 (19) . Given that monocytes are critically required for IL-2 production but not for IL-2 receptor expression in the course of primary immune responses (8) , monocyte failure can explain the profound incapacity of elaborating sufficient amounts of IL-2 with the consequence of immunodeficiency in vivo. That addition of recombinant human IL-2 fully reconstituted the abnormal proliferative responses of nonresponder lymphocytes after antigen-receptor triggering provides further support for this view (Table II) .
Most recently, we have investigated cellular immune functions of 9 HBsAg carriers on hemodialysis. Interestingly, each single individual presented with parameters that appear to correlate with nonresponsiveness to vaccination as observed here ( Fig. 1 and Fig. 2) . In all cases, enhanced functional T cell responses to rIL-2 were accompanied by strong expression of the Tac antigen following T cell receptor triggering and exposure to rIL-2 (compare Fig. 3) . 2 Given the enhanced sensitivity of such patients' IL-2 receptor system ( Fig. 2 and 3) , complete reconstitution was achieved with doses of IL-2 that, in the case of lymphocytes from healthy individuals, did not produce additional stimulatory effects (Table III) . Moreover, these experiments may be taken as evidence for the notion that nonresponder monocytes do not actively inhibit T cell activation. Although not shown, identical data were obtained employing autologous serum supplements to the in vitro system, indicating that soluble inhibitory activities are likely not related to the observed immunodeficiency.
Therefore, based on the present analysis, addition of IL-2 during vaccination may represent a useful strategy to circum-2. Meuer, S. C. Manuscript submitted for publication. vent the nonresponder state in vivo and perhaps improve on the overall immunodeficiency known to exist in patients with chronic renal failure.
